DUBLIN--(BUSINESS WIRE)--The "Drug analysis: Farxiga" drug pipelines has been added to ResearchAndMarkets.com's offering.
Farxiga (dapagliflozin; AstraZeneca) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion.
Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia. The drug was developed as part of a joint venture between AstraZeneca and Bristol-Myers Squibb. However, AstraZeneca has taken full ownership and marketing responsibilities after buying its partner's share of the venture.
Key Topics Covered:
List of Figures
Figure 1: Farxiga for type 2 diabetes - SWOT analysis
Figure 2: Drug assessment of Farxiga
Figure 3: Drug assessment scorecard for Farxiga compared to Januvia
Figure 4: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
Figure 5: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
Figure 6: Farxiga for type 1 diabetes - SWOT analysis
Figure 7: Drug assessment of Farxiga in type 1 diabetes
Figure 8: Drug assessment of Farxiga in type 1 diabetes
List of Tables
Table 1: Farxiga franchise products
Table 2: Farxiga drug profile
Table 3: Xigduo drug profile
Table 4: Overview of pivotal trial data for Farxiga in diabetes
Table 5: Key planned and ongoing Phase III clinical trials for Farxiga in diabetes
Table 6: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 7: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 8: Farxiga drug profile
Table 9: Farxiga late-phase trial in type 1 diabetes
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xjhhqh/farxiga?w=4
